Online inquiry

IVTScrip™ mRNA-Anti-TNFSF13B, BR3-Fc(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4777MR)

This product GTTS-WQ4777MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets TNFSF13B gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001145645.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 10673
UniProt ID Q9Y275
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFSF13B, BR3-Fc(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ4777MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ398MR IVTScrip™ mRNA-Anti-ANGPT2, 2xCon4C(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA 2xCon4C
GTTS-WQ14518MR IVTScrip™ mRNA-Anti-IL6R, SA-237(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA SA-237
GTTS-WQ6205MR IVTScrip™ mRNA-Anti-RABVgp4, CR4098(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CR4098
GTTS-WQ15745MR IVTScrip™ mRNA-Anti-SEMA4D, VX-15(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA VX-15
GTTS-WQ13341MR IVTScrip™ mRNA-Anti-PDCD1, PF-06801591(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA PF-06801591
GTTS-WQ12120MR IVTScrip™ mRNA-Anti-FOLR1, MORAb-003(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA MORAb-003
GTTS-WQ14416MR IVTScrip™ mRNA-Anti-IL2RA, RO 24-7375(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA RO 24-7375
GTTS-WQ10854MR IVTScrip™ mRNA-Anti-FOLR1, M9346A(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA M9346A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW